Alternatives

Life Sciences

We believe our Life Sciences team's deep expertise, extensive network, and advisory capabilities position us to identify the most promising, innovative companies developing the next generation of medicines.
wwd-life-sciences_21-9_1840x788.jpg

At a Glance

$1+
BillionCapital Raised
95
YearsOf life sciences experience on the investing team
21
Investments made to date

Source: Goldman Sachs Asset Management. Capital Raised as of June 30, 2026. Years of Experience and Investments made to date as of July 2026. Two preclinical portfolio companies currently in stealth. The team is unable to share additional details about the investments at this time. 

What Makes Us Different

Sourcing

We operate a robust, multi-channel sourcing engine that leverages Goldman Sachs’ relationships across academic and medical institutions, corporates, venture capital and private equity firms, and company founders and executives.

Capital Formation

We believe that many life sciences companies would benefit from scaling privately, but a funding gap has historically forced these companies to go public too early. By better aligning investment capital with company innovation, we hope to drive better outcomes for companies and, ultimately, patients.

Stage

We strive to invest in innovative life sciences companies developing novel medicines that are entering or in the earlier stages of clinical development.  By investing at a later-stage than traditional life sciences venture funds, Life Sciences at Goldman Sachs Alternatives seeks to mitigate scientific risk while retaining the significant value creation associated with clinical translation.  We believe the strategy has the potential to deliver strong returns over a shorter time period to our investors.

Value Creation

We partner with companies to enhance and accelerate value creation by helping them establish the right business and financial strategies, hire the right management team and board, execute, and achieve strong exits.

Investments by Stage of Development

All19
Table displaying portfolio company development progress since investment, with multiple companies advancing from Pre-DC or DC to Phase 1 or Phase 2 and two strategic exits.

Source: Goldman Sachs Asset Management as of July 2026. We believe the list of portfolio companies should be considered as a reflection of our investment process, and references to these particular assets/portfolio companies should not be considered a recommendation of any particular security, investment, or portfolio company. Any mention of an investment decision is intended only to illustrate our investment strategy and is not indicative of the performance of our strategy as a whole. It should not be assumed that any investment decisions shown will prove to be profitable or any future investment decisions will be profitable or equal the performance of the investments discussed herein. The holdings and/or allocations shown may not represent all of the strategy’s investments. Two preclinical portfolio companies currently in stealth. The team is unable to share additional details about the investments at this time. Please contact your Goldman Sachs Asset Management representative to obtain the holdings presented above as well as each holding’s contribution to performance and a complete list of past recommendations. Please see additional disclosures in the appendix.

Meet the Team

Our team comprises experienced life sciences investors with deep domain expertise across disciplines.
Our investment team is complemented by an industry leading Advisory Board comprised of academics, clinicians, scientific experts, and entrepreneurs.
Start the Conversation
Contact Goldman Sachs Asset Management for a detailed discussion of your needs.
card-poster